Allergan prepares Thursday note sale in five-, 10-year maturities

By Andrea Heisinger

New York, March 7 - Allergan, Inc. is expected to price notes (A3/A+/A+) in two maturities on Thursday, according to a filing with the Securities and Exchange Commission.

The sale includes a five-year note and 10-year note.

Active bookrunners are BofA Merrill Lynch and Goldman Sachs & Co. Passive bookrunners are Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC.

Proceeds will be used for general corporate purposes.

Allergan was last in the U.S. bond market with a $650 million sale of 3.375% 10-year notes priced at 80 basis points over Treasuries on Sept. 7, 2010.

The multi-specialty health care company is based in Irvine, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.